JP2016531910A5 - - Google Patents

Download PDF

Info

Publication number
JP2016531910A5
JP2016531910A5 JP2016534873A JP2016534873A JP2016531910A5 JP 2016531910 A5 JP2016531910 A5 JP 2016531910A5 JP 2016534873 A JP2016534873 A JP 2016534873A JP 2016534873 A JP2016534873 A JP 2016534873A JP 2016531910 A5 JP2016531910 A5 JP 2016531910A5
Authority
JP
Japan
Prior art keywords
organ
composition
complement inhibitor
complement
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016534873A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016531910A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/051323 external-priority patent/WO2015023972A1/en
Publication of JP2016531910A publication Critical patent/JP2016531910A/ja
Publication of JP2016531910A5 publication Critical patent/JP2016531910A5/ja
Pending legal-status Critical Current

Links

Images

JP2016534873A 2013-08-16 2014-08-15 移植前の臓器への補体阻害剤の投与による移植拒絶の処置 Pending JP2016531910A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361867009P 2013-08-16 2013-08-16
US61/867,009 2013-08-16
PCT/US2014/051323 WO2015023972A1 (en) 2013-08-16 2014-08-15 Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant

Publications (2)

Publication Number Publication Date
JP2016531910A JP2016531910A (ja) 2016-10-13
JP2016531910A5 true JP2016531910A5 (enExample) 2017-09-28

Family

ID=51494495

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016534873A Pending JP2016531910A (ja) 2013-08-16 2014-08-15 移植前の臓器への補体阻害剤の投与による移植拒絶の処置

Country Status (5)

Country Link
US (1) US20160184391A1 (enExample)
EP (1) EP3033093A1 (enExample)
JP (1) JP2016531910A (enExample)
CA (1) CA2920293A1 (enExample)
WO (1) WO2015023972A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4793360A2 (en) 2006-03-31 2026-08-19 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
TW201920257A (zh) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
TWI654203B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
CA2840270C (en) * 2011-06-22 2023-09-26 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
MX2017005774A (es) 2014-12-19 2017-07-28 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
EA201791366A1 (ru) 2014-12-19 2018-02-28 Чугаи Сейяку Кабусики Кайся Антитела к c5 и способы их применения
CN114773469B (zh) 2015-02-05 2025-12-19 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
EP3368073B1 (en) * 2015-10-30 2024-05-15 Alexion Pharmaceuticals, Inc. A method of inhibiting exacerbations of t cell-mediated allograft vasculopathy
CN108401431B (zh) 2015-12-18 2022-01-25 中外制药株式会社 抗-c5抗体及使用方法
WO2017212391A1 (en) * 2016-06-07 2017-12-14 Novartis Ag An anti-c5 antibody dosing regimen
EP3463459A1 (en) * 2016-06-07 2019-04-10 Novartis AG Tesidolumab for use in the treatment of transplant rejection
CN116271014A (zh) 2016-08-05 2023-06-23 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
WO2018075462A1 (en) * 2016-10-17 2018-04-26 Medical University Of South Carolina Compositions and methods for treating and preventing transplant-associated injury
GB201709222D0 (en) * 2017-06-09 2017-07-26 Univ Manchester C3b Inactivating Polypeptide
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
CN117044707A (zh) * 2018-08-17 2023-11-14 不列颠哥伦比亚大学 用于供体器官上的碳水化合物抗原切割的酶促组合物、与其相关的方法和用途
WO2020041644A1 (en) * 2018-08-22 2020-02-27 Alexion Pharmaceuticals, Inc. Fusion proteins and methods of treating complement dysregulation using the same
JP7502805B2 (ja) * 2019-03-21 2024-06-19 ザ ユーエイビー リサーチ ファウンデイション 補体媒介性溶解に対する細胞感受性を増加させる方法
AU2020272875A1 (en) 2019-04-10 2021-10-14 University Of Massachusetts Factor h vectors and uses thereof
CN110423271A (zh) * 2019-08-07 2019-11-08 北京市农林科学院 鸡cr2基因的克隆、蛋白的表达和纯化及其多克隆抗体的制备
WO2021257480A2 (en) 2020-06-14 2021-12-23 Catalyst Biosciences, Inc. Complement factor i-related compositions and methods
AU2022283254A1 (en) * 2021-05-25 2023-11-30 Alexion Pharmaceuticals, Inc. Kidney active fusion proteins and methods of treatment using the same

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5135916A (en) * 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
US5723282A (en) 1991-07-08 1998-03-03 The American National Red Cross Method of preparing organs for vitrification
US6074642A (en) * 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
DE69535920D1 (de) 1994-05-20 2009-04-09 Breonics Inc Verfahren zur überwachung der lebensfähigkeit transplantabler organe
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
IL137614A0 (en) 1998-02-04 2001-07-24 Gen Hospital Corp An inhibitor of a costimulatory pathway and hematopoietic stem cells for promoting graft acceptance
AU1521000A (en) 1998-11-06 2000-05-29 Schepens Eye Research Institute, Inc., The Local use of soluble tumor necrosis receptor i (stnfri) for prophylaxis and treatment of corneal transplant rejection and other disorders of the eye
AUPQ431299A0 (en) 1999-11-26 1999-12-23 Unisearch Limited Method of inducing immune tolerance
US6820011B2 (en) 2001-04-11 2004-11-16 The Regents Of The University Of Colorado Three-dimensional structure of complement receptor type 2 and uses thereof
US20030180301A1 (en) 2002-01-22 2003-09-25 Shaf Keshavjee Use of TGF-beta antagonists to treat or to prevent chronic transplant rejection
CA2558409A1 (en) * 2004-03-05 2005-09-22 Turbochef Technologies, Inc. Conveyor oven
EP2338511A3 (en) 2004-05-14 2012-07-25 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
US7745389B2 (en) 2005-02-14 2010-06-29 University Of Iowa Research Foundation Methods for treatment of age-related macular degeneration
BRPI0708424A2 (pt) * 2006-03-02 2011-05-31 Alexion Pharma Inc prolongamento da sobreviência de uma aloenxerto por inibição da atividade do complemento
JP5250548B2 (ja) * 2006-06-21 2013-07-31 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 疾患の治療のための補体ｈ因子の標的化
JP6223659B2 (ja) * 2008-11-10 2017-11-01 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体関連障害を処置するための方法および組成物
US20130323708A1 (en) 2009-07-01 2013-12-05 Massachusetts Institute Of Technology Isolated adult cells, artificial organs, rehabilitated organs, research tools, organ encasements, organ perfusion systems, and methods for preparing and utilizing the same

Similar Documents

Publication Publication Date Title
JP6466971B2 (ja) 臓器、組織又は細胞移植用組成物、キット及び移植方法
Patel et al. Therapeutic strategy with a membrane-localizing complement regulator to increase the number of usable donor organs after prolonged cold storage
JP2016531910A (ja) 移植前の臓器への補体阻害剤の投与による移植拒絶の処置
US20240350580A1 (en) Compositions and method for treating acute radiation syndrome
JP2022088551A (ja) 増殖造血幹細胞／前駆細胞集団の利用
JP7465567B2 (ja) Ｐｅｇ－リン脂質分子を用いたエクスビボ臓器処置
JP2009514553A5 (enExample)
CA2815237C (en) Method of improving transplant function using soluble complement receptor type i (scr1)
Dangoor et al. Transplantation: a brief history
US20200329698A1 (en) Compositions for organ graft preservation and methods of use
US10086070B2 (en) Combined therapy of alpha-1-antitrypsin and temporal T-cell depletion for preventing graft rejection
Anderson et al. Vaccinia virus complement control protein inhibits hyperacute xenorejection in a guinea pig-to-rat heterotopic cervical cardiac xenograft model by blocking both xenoantibody binding and complement pathway activation
JP6887628B2 (ja) 被移植体における移植不全を防ぐ方法
AU773516B2 (en) Organ transplant solutions containing conjugates of soluble peptidic compounds with membrane-binding
JP3543106B2 (ja) 膜結合型ｃ１インアクチベーター
JP2018519359A5 (enExample)
Hosgood et al. Cold ischaemic injury in kidney transplantation
RU2808054C2 (ru) Обработка органов ex vivo молекулами пэг-фосфолипида
JP6515429B2 (ja) 人工血管、および、人工血管の製造方法
WO2006019187A1 (ja) 腎障害治療剤
Xing et al. Liver regeneration: Influence-factors and mechanism of mesenchymal stem cell transplantation.
Lledó-Garcia et al. Optimizing outcomes by preconditioning the donor
Absaieri et al. Abo-Auda W, Benza RL. Therapeutic angiogenesis: review of current concepts and future directions. 2003; 22: 370-82 Abo-Auda W, Benza RL. Transmyocardial and percutane-ous myocardial revascularization: current concepts and
Șereș et al. A review of current strategies to overcome rejection in xenotransplant.
Xie TSG-6: An inducible mediator of paracrine anti-inflammatory and myeloprotective effects of adipose stem cells